Advertisement

125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review

  • 71 Accesses

Abstract

A systematic review was conducted to provide an overview of the efficacy and safety of 125I irradiation stent placement for patients with hepatocellular carcinoma (HCC) and main portal vein tumor thrombosis (MPVTT). Six studies with 406 patients were included in the final analysis. The median overall survival for patients treated with 125I irradiation stent placement was 10.3 months. The most common radiation-related adverse event was leukopenia. The stent-related adverse events consisted of fever, abdominal pain, hemorrhage, and anorexia. No stent or seed migration was reported. Overall, the use of an 125I irradiation stent has the potential to act as an alternative therapy for patients with HCC with MPVTT.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1

References

  1. 1.

    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

  2. 2.

    Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.

  3. 3.

    Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, et al. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol. 2017;9(10):615–26. https://doi.org/10.1177/1758834017728018.

  4. 4.

    Zhang ZM, Lai EC, Zhang C, Yu HW, Liu Z, Wan BJ, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015;20:8–16. https://doi.org/10.1016/j.ijsu.2015.05.009.

  5. 5.

    Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–7. https://doi.org/10.1002/hep.510290145.

  6. 6.

    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.

  7. 7.

    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.

  8. 8.

    Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9. https://doi.org/10.1016/j.jhep.2012.06.014.

  9. 9.

    Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48(10):1452–65. https://doi.org/10.1016/j.ejca.2011.12.006.

  10. 10.

    Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65(5):938–43. https://doi.org/10.1016/j.jhep.2016.05.044.

  11. 11.

    Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg. 2014;38(2):490–6. https://doi.org/10.1007/s00268-013-2290-4.

  12. 12.

    Lee DS, Seong J. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. Liver Cancer. 2014;3(1):18–30. https://doi.org/10.1159/000343855.

  13. 13.

    Inarrairaegui M, Thurston KG, Bilbao JI, D'Avola D, Rodriguez M, Arbizu J, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21(8):1205–12. https://doi.org/10.1016/j.jvir.2010.04.012.

  14. 14.

    Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36. https://doi.org/10.1016/S1470-2045(17)30683-6.

  15. 15.

    Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21. https://doi.org/10.1200/JCO.2017.76.0892.

  16. 16.

    Yamakado K, Tanaka N, Nakatsuka A, Matsumura K, Takase K, Takeda K. Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. J Hepatol. 1999;30(4):660–8.

  17. 17.

    Vibert E, Azoulay D, Cunha AS, Adam R, Samuel D, Castaing D. Portal stenting for hepatocellular carcinoma extending into the portal vein in cirrhotic patients. J Surg Oncol. 2013;107(7):696–701. https://doi.org/10.1002/jso.23306.

  18. 18.

    Guo JH, Teng GJ, Zhu GY, He SC, Fang W, Deng G, et al. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology. 2008;247(2):574–81. https://doi.org/10.1148/radiol.2472070999.

  19. 19.

    Zhu HD, Guo JH, Mao AW, Lv WF, Ji JS, Wang WH, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol. 2014;15(6):612–9. https://doi.org/10.1016/S1470-2045(14)70131-7.

  20. 20.

    Luo J, Yan Z, Liu Q, Qu X, Wang J. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. J Vasc Interv Radiol. 2011;22(4):479–89. https://doi.org/10.1016/j.jvir.2010.11.029.

  21. 21.

    Lu J, Guo JH, Zhu HD, Zhu GY, Chen L, Teng GJ. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma: a single-center experience. J Vasc Interv Radiol. 2017;28(6):786–94.e3. https://doi.org/10.1016/j.jvir.2017.02.014.

  22. 22.

    Peng SY, Wang XA, Huang CY, Li JT, Hong DF, Wang YF, et al. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol. 2018;24(40):4527–35. https://doi.org/10.3748/wjg.v24.i40.4527.

  23. 23.

    Wells GA SB, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2015. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

  24. 24.

    Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, et al. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol. 2017;23(43):7735–45. https://doi.org/10.3748/wjg.v23.i43.7735.

  25. 25.

    Yu TZ, Zhang W, Liu QX, Li WH, Ma JQ, Zhang ZH, et al. Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus. Oncotarget. 2017;8(7):12108–19. https://doi.org/10.18632/oncotarget.14520.

  26. 26.

    Sun JH, Zhou T, Zhu T, Zhang Y, Nie C, Ai J, et al. Portal vein stenting combined with Iodine-125 seeds endovascular implantation followed by transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma patients with portal vein tumor thrombus. Biomed Res Int. 2016;2016:3048261. https://doi.org/10.1155/2016/3048261.

  27. 27.

    Li CX, He X, Hu BS, Li Y, Shao PJ, Yu XY, et al. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer Biol Ther. 2011;12(10):865–71. https://doi.org/10.4161/cbt.12.10.17676.

  28. 28.

    Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2010;6(2):80–8. https://doi.org/10.1111/j.1743-7563.2010.01287.x.

  29. 29.

    Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis. Medicine (Baltimore). 2016;95(11):e3015. https://doi.org/10.1097/MD.0000000000003015.

  30. 30.

    Zhang XP, Gao YZ, Chen ZH, Chen MS, Li LQ, Wen TF, et al. An eastern hepatobiliary surgery hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study. Hepatology. 2018. https://doi.org/10.1002/hep.30490.

  31. 31.

    Yamakado K, Nakatsuka A, Tanaka N, Fujii A, Terada N, Takeda K. Malignant portal venous obstructions treated by stent placement: significant factors affecting patency. J Vasc Interv Radiol. 2001;12(12):1407–15.

  32. 32.

    Zhang FJ, Li CX, Jiao DC, Zhang NH, Wu PH, Duan GF, et al. CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma. Chin Med J (Engl). 2008;121(23):2410–4.

  33. 33.

    Zhu HD, Guo JH, Zhu GY, He SC, Fang W, Deng G, et al. A novel biliary stent loaded with (125)I seeds in patients with malignant biliary obstruction: preliminary results versus a conventional biliary stent. J Hepatol. 2012;56(5):1104–11. https://doi.org/10.1016/j.jhep.2011.12.018.

  34. 34.

    Zhang XB, Wang JH, Yan ZP, Qian S, Liu R. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting. Cardiovasc Intervent Radiol. 2009;32(1):52–61. https://doi.org/10.1007/s00270-008-9454-x.

  35. 35.

    DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver D. Vascular disorders of the liver Hepatology. 2009;49(5):1729–64. https://doi.org/10.1002/hep.22772.

  36. 36.

    Basili S, Raparelli V, Violi F. The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? Yes. Eur J Intern Med. 2010;21(2):62–4. https://doi.org/10.1016/j.ejim.2010.01.005.

  37. 37.

    Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(1):23–9. https://doi.org/10.1016/j.ejim.2014.12.002.

  38. 38.

    Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153(2):480–7e1. https://doi.org/10.1053/j.gastro.2017.04.042.

Download references

Acknowledgements

None.

Funding

This study was supported by the National Natural Science Foundation of China (81901847) and the Suzhou Science and Technology Youth Plan (KJXW2018003). Funding source had no involvement in the financial support for the conduct of the research and preparation of the article.

Author information

Correspondence to Bin-Yan Zhong or Cai-Fang Ni.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding authors state that there is no conflict of interest.

Consent for Publication

For this type of study, consent for publication is not required.

Human and Animal Rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent

For this type of study, informed consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhang, L., Hu, B., Li, W. et al. 125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. Cardiovasc Intervent Radiol 43, 196–203 (2020) doi:10.1007/s00270-019-02346-y

Download citation

Keywords

  • Hepatocellular carcinoma
  • Portal vein tumor thrombosis
  • Radioactive stent
  • Endovascular brachytherapy
  • Systematic review